|
covid-19 |
18 |
|
cardiovascular magnetic resonance |
14 |
|
type 2 diabetes |
11 |
|
4d flow |
9 |
|
anosmia |
9 |
|
chest x-ray |
9 |
|
imaging |
9 |
|
nomogram |
9 |
|
olfactory dysfunction |
9 |
|
prediction model |
9 |
|
sars-cov-2 |
9 |
|
smell impairment |
9 |
|
white cell count |
9 |
|
atherosclerosis |
8 |
|
cardiovascular diseases |
8 |
|
direct flow |
8 |
|
hfpef |
8 |
|
intraventricular flow |
8 |
|
multi-detector computed tomography |
8 |
|
residual volume |
8 |
|
rheumatoid arthritis |
8 |
|
asymptomatic |
6 |
|
coronary artery disease |
6 |
|
diastolic function |
6 |
|
high cardiovascular risk |
6 |
|
prognosis |
6 |
|
screening |
6 |
|
stress cardiac magnetic resonance |
6 |
|
adenosine triphosphate |
5 |
|
artificial intelligence |
5 |
|
outcome |
5 |
|
sex |
5 |
|
stress |
5 |
|
chest radiographs |
4 |
|
deep learning |
4 |
|
pneumonia |
4 |
|
valvular heart disease |
4 |
|
blood volume |
3 |
|
body composition |
3 |
|
cardiac capacity |
3 |
|
cardiac magnetic resonance imaging |
3 |
|
cardiac mri |
3 |
|
cardiorespiratory fitness |
3 |
|
cardiotoxicity |
3 |
|
circulating haemoglobin mass |
3 |
|
diabetes |
3 |
|
echocardiography |
3 |
|
echocardiography parameters |
3 |
|
epidemiological characteristics |
3 |
|
extracellular matrix |
3 |
|
fibrosis |
3 |
|
hans chinese |
3 |
|
lean body mass |
3 |
|
left ventricular function |
3 |
|
magnetic resonance imaging |
3 |
|
myocarditis |
3 |
|
older age |
3 |
|
pressure gradient manipulation |
3 |
|
prevalence |
3 |
|
prevalence in south-eastern chinese |
3 |
|
primary aldosteronism |
3 |
|
recovered |
3 |
|
refractory hypertension |
3 |
|
regional adiposity |
3 |
|
resistant hypertension |
3 |
|
right ventricular function |
3 |
|
serum uric acid |
3 |
|
sex dimorphism |
3 |
|
survivors |
3 |
|
target organ damage |
3 |
|
tetralogy of fallot |
3 |
|
tricuspid regurgitation |
3 |
|
troponin |
3 |
|
type 2 diabetic mellitus |
3 |
|
untreated hypertension |
3 |
|
venous return |
3 |
|
cardiac imaging |
2 |
|
cardiac magnetic resonance |
2 |
|
cardiovascular magnetic resonance imaging |
2 |
|
cardiovascular mortality |
2 |
|
cardiovascular system |
2 |
|
chronic kidney failure |
2 |
|
computed tomography |
2 |
|
coronary microvascular disease |
2 |
|
editorial |
2 |
|
hba1c variability |
2 |
|
heart failure |
2 |
|
infections |
2 |
|
machine learning |
2 |
|
mpri |
2 |
|
pulmonary atresia |
2 |
|
pulmonary regurgitation |
2 |
|
pulmonary stenosis |
2 |
|
severe acute respiratory syndrome coronavirus 2 |
2 |
|
stress cmr |
2 |
|
vector flow mapping |
2 |
|
4d flow cardiac mr |
1 |
|
agalsidase alfa |
1 |
|
alpha-galactosidase |
1 |
|
anatomy and physiology |
1 |
|
anderson-fabry disease |
1 |
|
antiplatelet therapy |
1 |
|
aorta |
1 |
|
beta-blocker |
1 |
|
breast cancer |
1 |
|
calcium score |
1 |
|
cardiac amyloidosis |
1 |
|
cardiac implantable electronic device |
1 |
|
cardiac tumors |
1 |
|
cardiology |
1 |
|
cardiomyopathy |
1 |
|
cmr |
1 |
|
competency |
1 |
|
computed tomography angiography |
1 |
|
congenital heart disease |
1 |
|
coronary artery calcium score |
1 |
|
coronary computed tomography angiography |
1 |
|
coronavirus infections |
1 |
|
curriculum |
1 |
|
dialysis |
1 |
|
dual bolus |
1 |
|
dual sequence |
1 |
|
early career |
1 |
|
empagliflozin |
1 |
|
end-stage renal disease |
1 |
|
epicardial fat |
1 |
|
exercise |
1 |
|
fabry disease |
1 |
|
feature tracking |
1 |
|
guidelines |
1 |
|
heart rate |
1 |
|
hemodialysis |
1 |
|
hypertrophy |
1 |
|
implantable cardioverter defibrillator |
1 |
|
ischemic heart disease |
1 |
|
late gadolinium enhancement |
1 |
|
left atrial function |
1 |
|
left atrium |
1 |
|
left ventricular morphology |
1 |
|
left ventricular strain |
1 |
|
lung diseases |
1 |
|
lv early diastolic strain rate |
1 |
|
lv peak systolic strain |
1 |
|
lvef |
1 |
|
meta-analysis |
1 |
|
mr safety |
1 |
|
mri physics |
1 |
|
mri safety |
1 |
|
myocardial blood flow |
1 |
|
myocardial deformation |
1 |
|
myocardial perfusion reserve |
1 |
|
myocardial scar |
1 |
|
myocardial strain |
1 |
|
non-ischemic cardiomyopathy |
1 |
|
obstructive coronary artery disease |
1 |
|
outcomes |
1 |
|
percutaneous coronary intervention |
1 |
|
pericardial disease |
1 |
|
prasugrel |
1 |
|
pretest probability |
1 |
|
pulmonary valve replacement |
1 |
|
pulmonary vein ct |
1 |
|
quantitative image analysis |
1 |
|
quantitative perfusion |
1 |
|
quantitative stress perfusion |
1 |
|
radiology |
1 |
|
right ventricle |
1 |
|
risk factor |
1 |
|
saxagliptin |
1 |
|
strain |
1 |
|
strain analysis |
1 |
|
stress cardiovascular magnetic resonance |
1 |
|
subclinical ventricular dysfunction |
1 |
|
t1 mapping |
1 |
|
ticagrelor |
1 |
|
tissue mapping |
1 |
|
tomography |
1 |
|
trastuzumab |
1 |
|
vasculitis |
1 |
|
ventricular function |
1 |
|
ventricular remodeling |
1 |
|
x-ray computed |
1 |
